Suppr超能文献

免疫抑制药物能减缓IgA肾病的进展吗?

Can immunosuppressive drugs slow the progression of IgA nephropathy?

作者信息

Goumenos D, Ahuja M, Shortland J R, Brown C B

机构信息

Sheffield Kidney Institute, Northern General Hospital NHS Trust, UK.

出版信息

Nephrol Dial Transplant. 1995;10(7):1173-81.

PMID:7478120
Abstract

The role of immunosuppressive drugs in the treatment of IgA nephropathy (IgAN) remains controversial. The effect of treatment with prednisolone and azathioprine on the clinical course of patients with IgA nephropathy is described in this retrospective study. One hundred and fourteen patients, 66 treated (age 13-77 years) and 48 untreated (age 15-64 years), were evaluated. The two groups of patients differed significantly with respect to heavier proteinuria (median 3.6 g/day, range 0.2-18 g/day), lower serum albumin level (< 40 g/l) and more severe renal histopathological involvement in the treated group (P < 0.01). Oral prednisolone 40 mg/day and azathioprine 2 mg/kg BW/day was commenced initially and after gradual tapering was continued at low dose (5 mg/day) for a median duration of 24 months (range 12-98). The median duration of follow-up was 46 months (range 12-180). The clinical course was defined as progressive or non-progressive on the basis of serial serum creatinine (Scr). Of the patients who presented with renal impairment (Scr > 110 mumol/l), a non-progressive course was observed in 79.5% patients of the treated group (n = 39), while only in 36% of the untreated group (n = 22), the difference was statistically significant (P < 0.001). Slopes of reciprocal of Scr versus time were also calculated by linear regression analysis to represent the trend of renal function for patients who had had 3 or more years follow-up (n = 101). An analysis of variance of these trends in patients with renal impairment at presentation (n = 51) showed significant recovery of renal function in the treated group (n = 33) and a decline of renal function in the untreated group (n = 18, P = 0.004). There was no significant effect of the treatment on proteinuria. The histopathological features that favoured response to the treatment were mesangial proliferation, capsular adhesions and interstitial infiltration on light-microscopy, C3 and fibrin deposits on immunofluorescence (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

免疫抑制药物在IgA肾病(IgAN)治疗中的作用仍存在争议。本回顾性研究描述了泼尼松龙和硫唑嘌呤治疗对IgA肾病患者临床病程的影响。共评估了114例患者,其中66例接受治疗(年龄13 - 77岁),48例未接受治疗(年龄15 - 64岁)。两组患者在蛋白尿更严重(中位数3.6 g/天,范围0.2 - 18 g/天)、血清白蛋白水平更低(< 40 g/l)以及治疗组肾组织病理学受累更严重方面存在显著差异(P < 0.01)。初始给予口服泼尼松龙40 mg/天和硫唑嘌呤2 mg/kg体重/天,逐渐减量后以低剂量(5 mg/天)持续使用,中位持续时间为24个月(范围12 - 98个月)。中位随访时间为46个月(范围12 - 180个月)。根据连续血清肌酐(Scr)将临床病程定义为进展性或非进展性。在出现肾功能损害(Scr > 110 μmol/l)的患者中,治疗组79.5%的患者(n = 39)观察到非进展性病程,而未治疗组仅36%的患者(n = 22)观察到,差异具有统计学意义(P < 0.001)。还通过线性回归分析计算了Scr倒数与时间的斜率,以代表随访3年或更长时间患者(n = 101)的肾功能趋势。对出现肾功能损害患者(n =

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验